| CAT # | Inoa Huahana | wehewehe |
| CPD100616 | Emricasan | ʻO Emricasan, ka mea i ʻike ʻia ʻo IDN 6556 a me PF 03491390, he mea hoʻopiʻi caspase papa mua i nā hoʻokolohua lapaʻau no ka mālama ʻana i nā maʻi ate. Hoʻemi ʻo Emricasan (IDN-6556) i ka hōʻeha o ka ate a me ka fibrosis i loko o kahi hiʻohiʻona murine o ka steatohepatitis non-alcoholic. Hoʻomaʻamaʻa ʻo IDN6556 i ka hoʻopili ʻana i nā mokupuni liʻiliʻi ma kahi kumu hoʻohālike autotransplant puaʻa. Hiki i ka waha IDN-6556 ke hoʻohaʻahaʻa i ka hana aminotransferase i nā poʻe maʻi me ka maʻi hepatitis C. Hoʻopaʻa ʻia ʻo PF-03491390 i loko o ke akepaʻa no nā manawa lōʻihi me ka haʻahaʻa haʻahaʻa o ka ʻōnaehana, e hana ana i kahi hopena hepatoprotective e kūʻē i ka hōʻeha ate alpha-fas-induced i loko o kahi kiʻi kiʻi. . |
| CPD100615 | Q-VD-Oph | ʻO QVD-OPH, ka mea i kapa ʻia ʻo Quinoline-Val-Asp-Difluorophenoxymethylketone, he mea hoʻopiʻi caspase ākea ākea me nā waiwai antiapoptotic ikaika. Kāohi ʻo Q-VD-OPh i ka hahau neonatal i ka ʻiole P7: he kuleana no ke kāne. Loaʻa i ka Q-VD-OPh nā hopena anti-leukemia a hiki ke launa pū me nā analogs vitamin D e hoʻonui i ka hōʻailona HPK1 i nā pūnaewele AML. Hoʻemi ʻo Q-VD-OPh i ka apoptosis i hoʻoulu ʻia i ka trauma a hoʻomaikaʻi i ka hoʻihoʻi ʻana o ka hana hope-lima i nā ʻiole ma hope o ka hōʻeha ʻana i ke kuamoʻo. |
| CPD100614 | Z-DEVD-FMK | ʻO Z-DEVD-fmk kahi mea paʻa i ka cell-permeable, hiki ʻole ke hoʻohuli ʻia o ka caspase-3. ʻO Caspase-3 kahi protease kikoʻī cysteinyl aspartate e pāʻani ana i kahi koʻikoʻi i ka apoptosis. |
| CPD100613 | Z-IETD-FMK | ʻO MDK4982, ka mea i kapa ʻia ʻo Z-IETD-FMK, he mea hoʻopaneʻe ikaika, cell-permeable, hiki ʻole ke hoʻololi ʻia o ka caspase-8 a me ka granzyme B., Na ka Caspase-8 Inhibitor II e hoʻomalu i ka hana biological o Caspase-8. Kāohi maikaʻi ʻo MDK4982 i ka apoptosis i hoʻokomo ʻia i ka maʻi maʻi influenza i nā cell HeLa. Kāohi pū ʻo MDK4982 i ka granzyme B. Loaʻa iā MDK4982 CAS #210344-98-2. |
| CPD100612 | Z-VAD-FMK | ʻO Z-VAD-FMK kahi mea hoʻopaneʻe pan-caspase hiki ke hoʻololi. Hoʻopaʻa ʻo Z-VAD-FMK i ka hana caspase a me ka hoʻokomo ʻana o ka apoptosis i loko o nā pūnaewele tumor in vitro (IC50 = 0.0015 - 5.8 mM). |
| CPD100611 | Belenacasan | ʻO Belnacasan, ka mea i kapa ʻia ʻo VX-765, ua hoʻolālā ʻia e kāohi i ka Caspase, ʻo ia ka enzyme e hoʻomalu i ka hana o ʻelua cytokines, IL-1b a me IL-18. Ua hōʻike ʻia ʻo VX-765 e kāohi i ka hopu ʻana i ka maʻi ma nā ʻano preclinical. Eia kekahi, ua hōʻike ʻo VX-765 i ka hana ma nā hiʻohiʻona preclinical o ka epilepsy maʻi. Ua kau ʻia ʻo VX-765 ma luna o 100 mau mea maʻi ma ka pae-I a me ka phase-IIa hoʻāʻo lapaʻau e pili ana i nā maʻi ʻē aʻe, me ka hoʻāʻo hoʻokolohua 28-lā phase-IIa i nā maʻi me psoriasis. Ua hoʻopau ʻo ia i ka lāʻau lapaʻau o kahi hoʻokolohua lapaʻau phase-IIa o VX-765 i hoʻopaʻa inoa ma kahi o 75 mau maʻi me ka maʻi epilepsy kūpaʻa. Ua hoʻolālā ʻia ka hoʻokolohua lapaʻau pālua-makapō, randomized, placebo-controlled clinical trial no ka loiloi i ka palekana, ka hoʻomanawanui a me ka hana lapaʻau o VX-765. |
